vs
莫德纳（MRNA）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是Rithm Capital Corp.的1.2倍（$1.0B vs $828.2M），Rithm Capital Corp.净利率更高（13.2% vs -19.7%，领先32.9%），Rithm Capital Corp.同比增速更快（-40.0% vs -45.4%），过去两年Rithm Capital Corp.的营收复合增速更高（-17.9% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
MRNA vs RITM — 直观对比
营收规模更大
MRNA
是对方的1.2倍
$828.2M
营收增速更快
RITM
高出5.4%
-45.4%
净利率更高
RITM
高出32.9%
-19.7%
两年增速更快
RITM
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $828.2M |
| 净利润 | $-200.0M | $109.5M |
| 毛利率 | 79.6% | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -19.7% | 13.2% |
| 营收同比 | -45.4% | -40.0% |
| 净利润同比 | -1638.5% | 20.9% |
| 每股收益（稀释后） | $-0.51 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNARITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $768.4M | ||
| Q4 24 | $966.0M | $2.1B | ||
| Q3 24 | $1.9B | $619.5M | ||
| Q2 24 | — | $1.2B |
净利润MRNARITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | — | $85.0M | ||
| Q3 25 | $-200.0M | $221.5M | ||
| Q2 25 | — | $311.7M | ||
| Q1 25 | — | $78.8M | ||
| Q4 24 | $-1.1B | $290.2M | ||
| Q3 24 | $13.0M | $121.7M | ||
| Q2 24 | — | $235.6M |
毛利率MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 79.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 72.4% | — | ||
| Q2 24 | — | — |
营业利润率MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | -25.6% | 21.4% | ||
| Q2 25 | — | 25.2% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | -129.0% | 23.8% | ||
| Q3 24 | -3.8% | 7.3% | ||
| Q2 24 | — | 23.6% |
净利率MRNARITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | — | 5.7% | ||
| Q3 25 | -19.7% | 20.0% | ||
| Q2 25 | — | 25.6% | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | -115.9% | 14.0% | ||
| Q3 24 | 0.7% | 19.7% | ||
| Q2 24 | — | 19.2% |
每股收益（稀释后）MRNARITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | — | $0.09 | ||
| Q3 25 | $-0.51 | $0.35 | ||
| Q2 25 | — | $0.53 | ||
| Q1 25 | — | $0.07 | ||
| Q4 24 | $-2.91 | $0.50 | ||
| Q3 24 | $0.03 | $0.20 | ||
| Q2 24 | — | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.3B | $9.1B |
| 总资产 | $12.1B | $53.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $1.9B | $1.5B | ||
| Q3 24 | $1.6B | $1.6B | ||
| Q2 24 | — | $1.2B |
总债务MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | — | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
股东权益MRNARITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | — | $8.4B | ||
| Q3 25 | $9.3B | $8.5B | ||
| Q2 25 | — | $7.9B | ||
| Q1 25 | — | $7.8B | ||
| Q4 24 | $10.9B | $7.8B | ||
| Q3 24 | $11.9B | $7.7B | ||
| Q2 24 | — | $7.3B |
总资产MRNARITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | — | $53.1B | ||
| Q3 25 | $12.1B | $47.2B | ||
| Q2 25 | — | $44.3B | ||
| Q1 25 | — | $45.3B | ||
| Q4 24 | $14.1B | $46.0B | ||
| Q3 24 | $15.8B | $42.3B | ||
| Q2 24 | — | $42.0B |
负债/权益比MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | — |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | — |
| 自由现金流率自由现金流/营收 | -86.6% | — |
| 资本支出强度资本支出/营收 | 3.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9B | — |
8季度趋势，按日历期对齐
经营现金流MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | $-114.6M | ||
| Q3 25 | $-847.0M | $-2.0B | ||
| Q2 25 | — | $-557.1M | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $825.0M | $-1.8B | ||
| Q3 24 | $-1.6B | $768.1M | ||
| Q2 24 | — | $-55.7M |
自由现金流MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-880.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $303.0M | — | ||
| Q3 24 | $-1.7B | — | ||
| Q2 24 | — | — |
自由现金流率MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -86.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 31.4% | — | ||
| Q3 24 | -92.2% | — | ||
| Q2 24 | — | — |
资本支出强度MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | — | — |
现金转化率MRNARITM
| Q1 26 | — | — | ||
| Q4 25 | — | -1.35× | ||
| Q3 25 | — | -9.22× | ||
| Q2 25 | — | -1.79× | ||
| Q1 25 | — | 18.03× | ||
| Q4 24 | — | -6.04× | ||
| Q3 24 | -120.46× | 6.31× | ||
| Q2 24 | — | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
